Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tavocept in combination with cisplatin and either docetaxel or paclitaxel · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Placebo in combination with cisplatin and either paclitaxel or docetaxel |
| Tavocept (BNP7787) | ACTIVE_COMPARATOR | Tavocept (BNP7787) in combination with cisplatin and either docetaxel or paclitaxel |
| Name | Type | Description |
|---|---|---|
| Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel | DRUG | Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks |
| Placebo in combination with cisplatin and docetaxel or paclitaxel | DRUG | Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks |
Inclusion Criteria: * Confirmed histopathological diagnosis of inoperable advanced primary adenocarcinoma (including bronchioalveolar cell carcinoma) of the lung * No prior systemic treatment for non-small cell lung cancer including chemotherapy, immunotherapy, hormonal therapy, targeted therapies ...
Top 20 of 83 competitors